RxDoctor Payments DataLook up a doctor →

Javier Munoz

Hematology & Oncology · Phoenix, AZNPI 1083823637

Payments from drug & device makers

$8,443,367in general payments, 2019–2025

Across 1,062 payments — averaging $7950.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$3.3M
  • Genentech, Inc.$1.9M
  • Gilead$1.7M
  • Beigene, Ltd.$351K
  • E.r. Squibb & Sons, L.L.C.$330K
  • Portola Pharmaceuticals, LLC$203K
  • plus $746K from 31 others
$9,481in research payments, 2019–2025

Across 20 payments — averaging $474.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$6K
  • F. Hoffmann-la Roche AG$2K
  • Gilead$1K
  • Bristol Myers Squibb$476

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,443,367 in reported general payments places this provider in the 95th percentile of 261 hematology & oncology providers in Arizona.

See all hematology & oncology providers in Arizona

Medicare billing

Part B allowed, 2024
$3,451,328
Medicare patients
869
Services billed
122,717

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →